Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia
- 1 June 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 18 (6), 507-514
- https://doi.org/10.1097/fpc.0b013e3282fc5801
Abstract
Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL). One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension. We determined the genotypes for 203 candidate polymorphisms in genes previously linked to hypertension or to the pharmacokinetics or pharmacodynamics of antileukemic agents. Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL. Of the 602 children with newly diagnosed ALL who were normotensive pretherapy, 270 (45%) developed hypertension during remission induction. None of the putative risk factors (age, sex, race, white blood cell count, risk group, body mass index, or serum creatinine) was associated with hypertension. Among the polymorphisms genotyped, we identified eight genes (CNTNAP2, LEPR, CRHR1, NTAN1, SLC12A3, ALPL, BGLAP, and APOB) containing variants that were associated with hypertension (chi2 P values 0.002-0.048), several of which interact with the hypothalamus-pituitary-adrenal axis. Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension. Hypertension is common during ALL remission induction and is related to germline genetic variation.Keywords
This publication has 41 references indexed in Scilit:
- Early Indicators of Dysmetabolic Syndrome in Young Survivors of Acute Lymphoblastic Leukemia in Childhood as a Target for Preventing DiseaseJournal of Pediatric Hematology/Oncology, 2007
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaJournal of Clinical Oncology, 2004
- Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2004
- Dexamethasone‐associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycinCancer, 2003
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Cardiovascular Risk Factors in Young Adult Survivors of Childhood Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2001
- Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their developmentLeukemia, 2001
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- High Incidence of Hypertension in Children Presenting with Acute Lymphoblastic LeukemiaPediatric Hematology and Oncology, 1994
- Unexpected Acute Neurologic Toxicity in the Treatment of Children With Acute Lymphoblastic LeukemiaJNCI Journal of the National Cancer Institute, 1992